Animal Models of Sepsis

Critical Care Clinics

Volumn 25, Issue 4, 2009, Pages 703-719

  Zanotti Cavazzoni, Sergio L ^a   Goldfarb, Roy D ^a  

^a Department of Anesthesiology   (United States)

Author keywords

Animal models; Drug development; Sepsis; Septic shock; Severe sepsis

Indexed keywords

ADJUVANT THERAPY; AGING; BODY SIZE; COMORBIDITY; DISEASE COURSE; DISEASE MODEL; DRUG SCREENING; EXPERIMENTAL ANIMAL; EXPERIMENTAL STUDY; HUMAN; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SEPSIS; SEPTIC SHOCK; SEX DIFFERENCE; ANIMAL; CECUM; HEMODYNAMICS; IMMUNOLOGY; LIGATION; PATHOPHYSIOLOGY;

ANIMALS; CECUM; COMORBIDITY; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HEMODYNAMICS; LIGATION; SEPSIS; SHOCK, SEPTIC;

EID: 70350519619     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2009.08.005     Document Type: Review

References (90)

1. Abraham E., Matthay M.A., Dinarello C.A., et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med 28 (2000) 232
2. Bone R.C., Balk R.A., Cerra F.B., et al., The ACCP/SCCM Consensus Conference Committee American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 (1992) 1644
3. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001) 1303
4. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699
5. Esper A.M., Moss M., Lewis C.A., et al. The role of infection and comorbidity: factors that influence disparities in sepsis. Crit Care Med 34 (2006) 2576
6. Marshall J.C., Deitch E., Moldawer L.L., et al. Preclinical models of shock and sepsis: what can they tell us?. Shock 24 Suppl 1 (2005) 1
7. Cohen J., Guyatt G., Bernard G.R., et al. New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 29 (2001) 880
8. Fink M.P., and Heard S.O. Laboratory models of sepsis and septic shock. J Surg Res 49 (1990) 186
9. Bockamp E., Maringer M., Spangenberg C., et al. Of mice and models: improved animal models for biomedical research. Physiol Genomics 11 (2002) 115
10. Food and Drug Administration. Nonclinical evaluation for anticancer pharmaceuticals. 2009.
11. Guidance for industry; providing regulatory submissions in electronic format-NDAs (1999), US Dept Health, Center for drug Evaluation and Research
12. Marshall J.C. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2 (2003) 391
13. Dyson A., and Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?. Crit Care Med 37 (2009) S30
14. Esmon C.T. Why do animal models (sometimes) fail to mimic human sepsis?. Crit Care Med 32 (2004) S219
15. Opal S.M., and Patrozou E. Translational research in the development of novel sepsis therapeutics: logical deductive reasoning or mission impossible?. Crit Care Med 37 (2009) S10
16. Buras J.A., Holzmann B., and Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4 (2005) 854
17. Remick D.G., and Ward P.A. Evaluation of endotoxin models for the study of sepsis. Shock 24 Suppl 1 (2005) 7
18. Kumar A., Zanotti S., Bunnell G., et al. Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response. Crit Care Med 33 (2005) 331
19. Remick D.G., Newcomb D.E., Bolgos G.L., et al. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13 (2000) 110
20. Suffredini A.F., Fromm R.E., Parker M.M., et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321 (1989) 280
21. Rosser D.M., Stidwill R.P., Jacobson D., et al. Oxygen tension in the bladder epithelium rises in both high and low cardiac output endotoxemic sepsis. J Appl Physiol 79 (1995) 1878
22. Cross A.S., Opal S.M., Sadoff J.C., et al. Choice of bacteria in animal models of sepsis. Infect Immun 61 (1993) 2741
23. Deitch E.A. Rodent models of intra-abdominal infection. Shock 24 Suppl 1 (2005) 19
24. Poli-de-Figueiredo L.F., Garrido A.G., Nakagawa N., et al. Experimental models of sepsis and their clinical relevance. Shock 30 Suppl 1 (2008) 53
25. Wichterman K.A., Baue A.E., and Chaudry I.H. Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res 29 (1980) 189
26. Brealey D., Karyampudi S., Jacques T.S., et al. Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 286 (2004) R491
27. Goldfarb R.D., Dellinger R.P., and Parrillo J.E. Porcine models of severe sepsis: emphasis on porcine peritonitis. Shock 24 Suppl 1 (2005) 75
28. Mathiak G., Szewczyk D., Abdullah F., et al. An improved clinically relevant sepsis model in the conscious rat. Crit Care Med 28 (2000) 1947
29. Villa P., Sartor G., Angelini M., et al. Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol 2 (1995) 549
30. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 (2008) 296
31. Hollenberg S.M., Ahrens T.S., Annane D., et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 32 (2004) 1928
32. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 (2006) 1589
33. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001) 1368
34. Kumar A., Haery C., Paladugu B., et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 193 (2006) 251
35. Smith III E.F., Slivjak M.J., Egan J.W., et al. Fluid resuscitation improves survival of endotoxemic or septicemic rats: possible contribution of tumor necrosis factor. Pharmacology 46 (1993) 254
36. Zanotti-Cavazzoni S.L., Guglielmi M., Parrillo J.E., et al. Fluid resuscitation influences cardiovascular performance and mortality in a murine model of sepsis. Intensive Care Med 35 (2009) 748
37. Hollenberg S.M., Dumasius A., Easington C., et al. Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography. Am J Respir Crit Care Med 164 (2001) 891
38. Piper R.D., Cook D.J., Bone R.C., et al. Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 24 (1996) 2059
39. Copeland S., Warren H.S., Lowry S.F., et al. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 12 (2005) 60
40. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546
41. Padkin A., Goldfrad C., Brady A.R., et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 31 (2003) 2332
42. Martin G.S., Mannino D.M., and Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 34 (2006) 15
43. Turnbull I.R., Wlzorek J.J., Osborne D., et al. Effects of age on mortality and antibiotic efficacy in cecal ligation and puncture. Shock 19 (2003) 310
44. Turnbull I.R., Buchman T.G., Javadi P., et al. Age disproportionately increases sepsis-induced apoptosis in the spleen and gut epithelium. Shock 22 (2004) 364
45. Chorinchath B.B., Kong L.Y., Mao L., et al. Age-associated differences in TNF-alpha and nitric oxide production in endotoxic mice. J Immunol 156 (1996) 1525
46. Tateda K., Matsumoto T., Miyazaki S., et al. Lipopolysaccharide-induced lethality and cytokine production in aged mice. Infect Immun 64 (1996) 769
47. Laterre P.F., Levy H., Clermont G., et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 32 (2004) 2207
48. Kher A., Wang M., Tsai B.M., et al. Sex differences in the myocardial inflammatory response to acute injury. Shock 23 (2005) 1
49. Knoferl M.W., Angele M.K., Diodato M.D., et al. Female sex hormones regulate macrophage function after trauma-hemorrhage and prevent increased death rate from subsequent sepsis. Ann Surg 235 (2002) 105
50. Merkel S.M., Alexander S., Zufall E., et al. Essential role for estrogen in protection against Vibrio vulnificus-induced endotoxic shock. Infect Immun 69 (2001) 6119
51. Deitch E.A. Animal models of sepsis and shock: a review and lessons learned. Shock 9 (1998) 1
52. Rittirsch D., Hoesel L.M., and Ward P.A. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 81 (2007) 137
53. Hubbard W.J., Choudhry M., Schwacha M.G., et al. Cecal ligation and puncture. Shock 24 Suppl 1 (2005) 52
54. Rittirsch D., Huber-Lang M.S., Flierl M.A., et al. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 4 (2009) 31
55. Singleton K.D., and Wischmeyer P.E. Distance of cecum ligated influences mortality, tumor necrosis factor-alpha and interleukin-6 expression following cecal ligation and puncture in the rat. Eur Surg Res 35 (2003) 486
56. Baker C.C., Chaudry I.H., Gaines H.O., et al. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94 (1983) 331
57. Rittirsch D., Flierl M.A., Nadeau B.A., et al. Functional roles for C5a receptors in sepsis. Nat Med 14 (2008) 551
58. Newcomb D., Bolgos G., Green L., et al. Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock 10 (1998) 110
59. Zantl N., Uebe A., Neumann B., et al. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun 66 (1998) 2300
60. Maier S., Traeger T., Entleutner M., et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock 21 (2004) 505
61. Emmanuilidis K., Weighardt H., Maier S., et al. Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. J Immunol 167 (2001) 3919
62. Feterowski C., Mack M., Weighardt H., et al. CC chemokine receptor 2 regulates leukocyte recruitment and IL-10 production during acute polymicrobial sepsis. Eur J Immunol 34 (2004) 3664
63. Redl H., and Bahrami S. Large animal models: baboons for trauma, shock, and sepsis studies. Shock 24 Suppl 1 (2005) 88
64. Hinshaw L.B. Application of animal shock models to the human. Circ Shock 17 (1985) 205
65. Reilly P.M., Wilkins K.B., Fuh K.C., et al. The mesenteric hemodynamic response to circulatory shock: an overview. Shock 15 (2001) 329
66. Michie H.R. The value of animal models in the development of new drugs for the treatment of the sepsis syndrome. J Antimicrob Chemother 41 Suppl A (1998) 47
67. Pittet J.F., Pastor C.M., and Morel D.R. Spontaneous high systemic oxygen delivery increases survival rate in awake sheep during sustained endotoxemia. Crit Care Med 28 (2000) 496
68. Sloane P.J., Elsasser T.H., Spath Jr. J.A., et al. Plasma tumor necrosis factor-alpha during long-term endotoxemia in awake sheep. J Appl Physiol 73 (1992) 1831
69. Nakasawa H., Noda H., and Traber L.D. Endotoxin induced elevation of lung fluid flux is not caused by increased permeability to protein but to small molecules. Circ Shock 37 (1992) 39
70. Fischer S.R., Bone H.G., Powell W.C., et al. Pyridoxalated hemoglobin polyoxyethylene conjugate does not restore hypoxic pulmonary vasoconstriction in ovine sepsis. Crit Care Med 25 (1997) 1551
71. Fischer S.R., Deyo D.J., Bone H.G., et al. Nitric oxide synthase inhibition restores hypoxic pulmonary vasoconstriction in sepsis. Am J Respir Crit Care Med 156 (1997) 833
72. Noda H., Noshima S., Nakazawa H., et al. Left ventricular dysfunction and acute lung injury induced by continuous administration of endotoxin in sheep. Shock 1 (1994) 291
73. Saetre T., Lindgaard A.K., and Lyberg T. Systemic activation of coagulation and fibrynolysis in a porcine model of serogroup A streptococcal shock. Blood Coagul Fibrinolysis 11 (2000) 433
74. Goldfarb R.D., Parker T.S., Levine D.M., et al. Protein-free phospholipid emulsion treatment improved cardiopulmonary function and survival in porcine sepsis. Am J Physiol Regul Integr Comp Physiol 284 (2003) R550
75. Aranow J.S., Wang H., Zhuang J., et al. Effect of human hemoglobin on systemic and regional hemodynamics in a porcine model of endotoxemic shock. Crit Care Med 24 (1996) 807
76. Vassilev D., Hauser B., Bracht H., et al. Systemic, pulmonary, and hepatosplanchnic effects of N-acetylcysteine during long-term porcine endotoxemia. Crit Care Med 32 (2004) 525
77. Murphey E.D., and Traber D.L. Pretreatment with tumor necrosis factor-alpha attenuates arterial hypotension and mortality induced by endotoxin in pigs. Crit Care Med 28 (2000) 2015
78. Lee K., van der Zee H., Dziuban Jr. S.W., et al. Left ventricular function during chronic endotoxemia in swine. Am J Physiol 254 (1988) H324
79. Dickneite G., and Kroez M. Treatment of porcine sepsis with high-dose antithrombin III reduces tissue edema and effusion but does not increase risk for bleeding. Blood Coagul Fibrinolysis 12 (2001) 4559
80. Nielsen O.L., Iburg T., Analbaek B., et al. A pig model of acute Staphylococcus aureus induced pyemia. Acta Vet Scand 51 (2009) 14
81. Swindel M.M., Smith A.C., and Hepburn B.J. Swine as models in experimental surgery. Invest Surg 1 (1988) 65
82. Eichacker P.Q., Danner R.L., Suffredini A.F., et al. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Crit Care Med 33 (2005) 2426
83. Sweeney D.A., Danner R.L., Eichacker P.Q., et al. Once is not enough: clinical trials in sepsis. Intensive Care Med 34 (2008) 1955
84. Sweeney D.A., Natanson C., and Eichacker P.Q. Recombinant human activated protein C, package labeling, and hemorrhage risks. Crit Care Med 37 (2009) 327
85. Marshall J.C., Vincent J.L., Guyatt G., et al. Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med 33 (2005) 1708
86. Eichacker P.Q., Parent C., Kalil A., et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166 (2002) 1197
87. Kaufmann S.H. Paul Ehrlich: founder of chemotherapy. Nat Rev Drug Discov 7 (2008) 373
88. Calvano S.E., Xiao W., Richards D.R., et al. A network-based analysis of systemic inflammation in humans. Nature 437 (2007) 1032-1039
89. Goldfarb R.D., Gandhi S., Cinel I., et al. Escherichia coli porcine peritonitis induces histological and transcriptome evidence of cardiac injury. Critical Care 11 Suppl 2 (2007) P13
90. Cobb J.P., Mindrinos M.N., Miller-Graziano C., et al. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A 102 13 (2005) 4801-4806